BGI, China
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) (NCT06499025) | BGI, China | 2024-02-01 |
| Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T (NCT06224049) | BGI, China | 2023-12-01 |
| HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors (NCT05895370) | BGI, China | 2023-04-13 |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) (NCT05798533) | BGI, China | 2023-01-10 |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) (NCT05798546) | BGI, China | 2022-09-28 |
| TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor (NCT03185429) | BGI, China | 2017-12-01 |
Track BGI, China automatically
Every clearance here is in the API, with alerts when new ones post.